Literature DB >> 27026780

Pelvic recurrence of stage 1a well-differentiated endometrial carcinoma after 13 years: A case report.

Annie Kim1, Long Nguyen2, Tamara Kalir3, Linus Chuang2.   

Abstract

A great majority of endometrial carcinoma recurrences are observed in high-risk patients and within the first 3 years of treatment. The relapse of endometrial carcinoma occurring more than 10 years after initial treatment has rarely been described. Initially diagnosed and treated for International Federation of Gynecology and Obstetrics (FIGO) stage 1a, grade 1 adenocarcinoma, our patient presented 13 years later with an isolated pelvic recurrence, demonstrating, to our knowledge, the longest disease-free interval with recurrence in the pelvis reported in literature. After surgical resection, the patient is being considered for enrollment in a clinical trial. Despite favorable prognostic features, it is possible to observe the recurrence of endometrial carcinoma even 5 years after surveillance and remission. Successful salvage therapies are available but may depend upon early diagnosis.

Entities:  

Keywords:  Endometrial carcinoma; disease-free interval; recurrence

Year:  2016        PMID: 27026780      PMCID: PMC4794293          DOI: 10.5152/jtgga.2015.0172

Source DB:  PubMed          Journal:  J Turk Ger Gynecol Assoc        ISSN: 1309-0380


  12 in total

1.  Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study.

Authors:  E Sartori; B Laface; A Gadducci; T Maggino; P Zola; F Landoni; V Zanagnolo
Journal:  Int J Gynecol Cancer       Date:  2003 Jul-Aug       Impact factor: 3.437

2.  Late recurrence of uterine endometrioid carcinoma in the upper urinary tract.

Authors:  Yuzuri Tsurumaki; Haruki Kume; Yukio Homma
Journal:  Arch Gynecol Obstet       Date:  2009-02-07       Impact factor: 2.344

3.  Outcomes of patients with low-risk endometrial cancer surgically staged without lymphadenectomy based on intra-operative evaluation.

Authors:  Jeffrey G Bell; Diana M Patterson; Jennifer Klima; Michelle Harvison; Kellie Rath; Gary Reid
Journal:  Gynecol Oncol       Date:  2014-07-05       Impact factor: 5.482

Review 4.  An unusual rectosigmoid mass: endometrioid adenocarcinoma arising in colonic endometriosis: case report and literature review.

Authors:  Chuong D Hoang; Adam K Boettcher; Jose Jessurun; Stefan E Pambuccian; Kelli M Bullard
Journal:  Am Surg       Date:  2005-08       Impact factor: 0.688

5.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

6.  Endometrial carcinoma recurrence in an abdominal scar 14 years after total hysterectomy.

Authors:  U Lorenz; A M Gassel; A Thiede; H J Gassel
Journal:  Gynecol Oncol       Date:  2004-11       Impact factor: 5.482

7.  Late recurrence in endometrial carcinoma.

Authors:  G S Lederman; J M Niloff; R Redline; E M Rosen
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

Review 8.  Advances in the management of recurrent endometrial cancer.

Authors:  Leslie S Bradford; Jose Alejandro Rauh-Hain; John Schorge; Michael J Birrer; Don S Dizon
Journal:  Am J Clin Oncol       Date:  2015-04       Impact factor: 2.339

9.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.

Authors:  Henry M Keys; James A Roberts; Virginia L Brunetto; Richard J Zaino; Nick M Spirtos; Jeffrey D Bloss; Andrew Pearlman; Mitchell A Maiman; Jeffrey G Bell
Journal:  Gynecol Oncol       Date:  2004-03       Impact factor: 5.482

10.  Vaginal recurrence more than 17 years after hysterectomy and adjuvant treatment for uterine carcinoma with successful salvage brachytherapy: a case report.

Authors:  Raphael Yechieli; Jared R Robbins; Daniel Schultz; Adnan Munkarah; Mohamed A Elshaikh
Journal:  Case Rep Oncol       Date:  2011-04-18
View more
  2 in total

1.  MicroRNA-340 Inhibits Tumor Cell Proliferation and Induces Apoptosis in Endometrial Carcinoma Cell Line RL 95-2.

Authors:  Wei Xie; Wen Qin; Yalin Kang; Ziyan Zhou; Aiping Qin
Journal:  Med Sci Monit       Date:  2016-05-06

2.  Bu Shen Yang Xue Prescription Has Treating Effect on Endometrial Cancer through FSH/PI3K/AKT/Gankyrin/HIF-α/cyclinD 1 Pathway in Ishikawa Cells.

Authors:  Yue-Qun Chen; Hua-Li Fei; Hong-Li Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-09       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.